TW202114676A - 治療癌症之方法 - Google Patents

Info

Publication number

TW202114676A

TW202114676A TW109127558A TW109127558A TW202114676A TW 202114676 A TW202114676 A TW 202114676A TW 109127558 A TW109127558 A TW 109127558A TW 109127558 A TW109127558 A TW 109127558A TW 202114676 A TW202114676 A TW 202114676A

Authority

TW

Taiwan

Prior art keywords

patient

entratinib

administration

cancer

grade

Prior art date

2019-08-14

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 330
• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 322
• 201000011510 cancer Diseases 0.000 title claims abstract description 249
• 206010067484 Adverse reaction Diseases 0.000 claims abstract description 192
• 230000006838 adverse reaction Effects 0.000 claims abstract description 192
• 230000003908 liver function Effects 0.000 claims abstract description 44
• 230000001771 impaired effect Effects 0.000 claims abstract description 25
• 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims description 141
• 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims description 141
• 230000002829 reductive effect Effects 0.000 claims description 130
• 206010019280 Heart failures Diseases 0.000 claims description 105
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 102
• 208000024891 symptom Diseases 0.000 claims description 92
• 210000003169 central nervous system Anatomy 0.000 claims description 76
• 108090000623 proteins and genes Proteins 0.000 claims description 75
• 102000003929 Transaminases Human genes 0.000 claims description 58
• 108090000340 Transaminases Proteins 0.000 claims description 58
• 208000010877 cognitive disease Diseases 0.000 claims description 52
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 51
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 51
• 201000002528 pancreatic cancer Diseases 0.000 claims description 51
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 51
• 231100000304 hepatotoxicity Toxicity 0.000 claims description 48
• 208000028698 Cognitive impairment Diseases 0.000 claims description 46
• 201000001431 Hyperuricemia Diseases 0.000 claims description 46
• 238000011282 treatment Methods 0.000 claims description 45
• 239000003814 drug Substances 0.000 claims description 44
• 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 39
• 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 39
• 208000004235 neutropenia Diseases 0.000 claims description 34
• 206010019851 Hepatotoxicity Diseases 0.000 claims description 33
• 230000007686 hepatotoxicity Effects 0.000 claims description 33
• 229940079593 drug Drugs 0.000 claims description 32
• 206010047571 Visual impairment Diseases 0.000 claims description 31
• 208000007502 anemia Diseases 0.000 claims description 31
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 30
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 30
• 208000010392 Bone Fractures Diseases 0.000 claims description 29
• 230000008859 change Effects 0.000 claims description 29
• 206010017076 Fracture Diseases 0.000 claims description 28
• 208000029257 vision disease Diseases 0.000 claims description 27
• 230000004393 visual impairment Effects 0.000 claims description 26
• 239000003792 electrolyte Substances 0.000 claims description 22
• 238000008050 Total Bilirubin Reagent Methods 0.000 claims description 21
• 210000002966 serum Anatomy 0.000 claims description 21
• 230000004927 fusion Effects 0.000 claims description 19
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 18
• 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims description 17
• 206010009944 Colon cancer Diseases 0.000 claims description 17
• 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims description 17
• 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims description 17
• 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 17
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 17
• 230000002035 prolonged effect Effects 0.000 claims description 17
• 229940116269 uric acid Drugs 0.000 claims description 17
• 102100029166 NT-3 growth factor receptor Human genes 0.000 claims description 16
• 238000011084 recovery Methods 0.000 claims description 16
• 108010064892 trkC Receptor Proteins 0.000 claims description 16
• 230000001149 cognitive effect Effects 0.000 claims description 15
• 230000007056 liver toxicity Effects 0.000 claims description 15
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 14
• 206010039491 Sarcoma Diseases 0.000 claims description 14
• 230000005856 abnormality Effects 0.000 claims description 13
• 238000012360 testing method Methods 0.000 claims description 13
• 210000004185 liver Anatomy 0.000 claims description 12
• 206010008635 Cholestasis Diseases 0.000 claims description 11
• 206010018910 Haemolysis Diseases 0.000 claims description 11
• 230000007870 cholestasis Effects 0.000 claims description 11
• 231100000359 cholestasis Toxicity 0.000 claims description 11
• 230000008588 hemolysis Effects 0.000 claims description 11
• 206010014418 Electrolyte imbalance Diseases 0.000 claims description 10
• 208000004547 Hallucinations Diseases 0.000 claims description 10
• 206010003119 arrhythmia Diseases 0.000 claims description 10
• 230000006793 arrhythmia Effects 0.000 claims description 10
• 230000000306 recurrent effect Effects 0.000 claims description 10
• 208000018452 Torsade de pointes Diseases 0.000 claims description 9
• 208000002363 Torsades de Pointes Diseases 0.000 claims description 9
• 230000002068 genetic effect Effects 0.000 claims description 9
• 238000002483 medication Methods 0.000 claims description 9
• 238000012544 monitoring process Methods 0.000 claims description 9
• 208000014321 polymorphic ventricular tachycardia Diseases 0.000 claims description 9
• 206010042772 syncope Diseases 0.000 claims description 9
• 206010047302 ventricular tachycardia Diseases 0.000 claims description 9
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 8
• 206010006187 Breast cancer Diseases 0.000 claims description 8
• 208000026310 Breast neoplasm Diseases 0.000 claims description 8
• 230000006735 deficit Effects 0.000 claims description 8
• 230000001988 toxicity Effects 0.000 claims description 7
• 231100000419 toxicity Toxicity 0.000 claims description 7
• 230000006996 mental state Effects 0.000 claims description 5
• 230000004768 organ dysfunction Effects 0.000 claims description 5
• 208000026139 Memory disease Diseases 0.000 claims description 4
• 101100091501 Mus musculus Ros1 gene Proteins 0.000 claims description 4
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
• 208000019622 heart disease Diseases 0.000 claims description 4
• 208000019423 liver disease Diseases 0.000 claims description 4
• 206010003445 Ascites Diseases 0.000 claims description 3
• 208000014644 Brain disease Diseases 0.000 claims description 3
• 208000032274 Encephalopathy Diseases 0.000 claims description 3
• 208000029523 Interstitial Lung disease Diseases 0.000 claims description 3
• 102100027378 Prothrombin Human genes 0.000 claims description 3
• 108010094028 Prothrombin Proteins 0.000 claims description 3
• 108010071390 Serum Albumin Proteins 0.000 claims description 3
• 102000007562 Serum Albumin Human genes 0.000 claims description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 229940039716 prothrombin Drugs 0.000 claims description 3
• 201000002510 thyroid cancer Diseases 0.000 claims description 3
• 201000007452 breast secretory carcinoma Diseases 0.000 claims description 2
• 230000005976 liver dysfunction Effects 0.000 claims description 2
• 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
• 231100000748 severe hepatic injury Toxicity 0.000 claims description 2
• 238000011156 evaluation Methods 0.000 claims 1
• 231100000847 severe hepatotoxicity Toxicity 0.000 claims 1
• HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 abstract description 4
• 229950000521 entrectinib Drugs 0.000 abstract 2
• 210000004027 cell Anatomy 0.000 description 117
• 239000008194 pharmaceutical composition Substances 0.000 description 114
• 101150111783 NTRK1 gene Proteins 0.000 description 99
• 101150117329 NTRK3 gene Proteins 0.000 description 98
• 101150056950 Ntrk2 gene Proteins 0.000 description 98
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 92
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 84
• 206010019670 Hepatic function abnormal Diseases 0.000 description 83
• 230000009467 reduction Effects 0.000 description 71
• 230000000694 effects Effects 0.000 description 59
• -1 antibodies Substances 0.000 description 55
• 206010067482 No adverse event Diseases 0.000 description 54
• 230000007547 defect Effects 0.000 description 43
• 230000002411 adverse Effects 0.000 description 40
• 239000003112 inhibitor Substances 0.000 description 40
• 239000002246 antineoplastic agent Substances 0.000 description 39
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 38
• 108010082126 Alanine transaminase Proteins 0.000 description 38
• 230000002159 abnormal effect Effects 0.000 description 37
• 241000124008 Mammalia Species 0.000 description 35
• 238000012217 deletion Methods 0.000 description 32
• 230000037430 deletion Effects 0.000 description 32
• 239000000203 mixture Substances 0.000 description 32
• 239000000090 biomarker Substances 0.000 description 31
• 230000035772 mutation Effects 0.000 description 29
• 230000010261 cell growth Effects 0.000 description 27
• 239000000523 sample Substances 0.000 description 23
• 238000003556 assay Methods 0.000 description 22
• 239000012472 biological sample Substances 0.000 description 21
• 210000001519 tissue Anatomy 0.000 description 21
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
• 230000003828 downregulation Effects 0.000 description 19
• 206010013975 Dyspnoeas Diseases 0.000 description 18
• 239000003795 chemical substances by application Substances 0.000 description 18
• 150000001875 compounds Chemical class 0.000 description 18
• 208000002173 dizziness Diseases 0.000 description 18
• 230000014509 gene expression Effects 0.000 description 18
• 206010029260 Neuroblastoma Diseases 0.000 description 17
• 230000003827 upregulation Effects 0.000 description 17
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
• 150000007523 nucleic acids Chemical class 0.000 description 16
• 208000000059 Dyspnea Diseases 0.000 description 15
• 239000004037 angiogenesis inhibitor Substances 0.000 description 14
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
• 230000002354 daily effect Effects 0.000 description 14
• 102000004169 proteins and genes Human genes 0.000 description 14
• 206010030113 Oedema Diseases 0.000 description 13
• 239000002775 capsule Substances 0.000 description 13
• 230000001404 mediated effect Effects 0.000 description 13
• 208000019022 Mood disease Diseases 0.000 description 12
• 108010025020 Nerve Growth Factor Proteins 0.000 description 12
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 12
• 201000010099 disease Diseases 0.000 description 12
• 235000018102 proteins Nutrition 0.000 description 12
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 12
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 11
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 11
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 11
• 208000010201 Exanthema Diseases 0.000 description 11
• 101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 description 11
• 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 description 11
• 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 11
• 102000015336 Nerve Growth Factor Human genes 0.000 description 11
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 11
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 11
• 102100029268 Neurotrophin-3 Human genes 0.000 description 11
• 102100033857 Neurotrophin-4 Human genes 0.000 description 11
• 230000027455 binding Effects 0.000 description 11
• 201000005884 exanthem Diseases 0.000 description 11
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
• 206010037844 rash Diseases 0.000 description 11
• 208000019116 sleep disease Diseases 0.000 description 11
• 239000007787 solid Substances 0.000 description 11
• 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 10
• 229940127089 cytotoxic agent Drugs 0.000 description 10
• 238000001514 detection method Methods 0.000 description 10
• 206010016256 fatigue Diseases 0.000 description 10
• 230000004077 genetic alteration Effects 0.000 description 10
• 231100000118 genetic alteration Toxicity 0.000 description 10
• 230000019491 signal transduction Effects 0.000 description 10
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 9
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
• 206010025323 Lymphomas Diseases 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 208000009956 adenocarcinoma Diseases 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 230000001105 regulatory effect Effects 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 8
• 206010035664 Pneumonia Diseases 0.000 description 8
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
• 230000033228 biological regulation Effects 0.000 description 8
• 238000001574 biopsy Methods 0.000 description 8
• 208000035475 disorder Diseases 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 239000000945 filler Substances 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 8
• 229960001375 lactose Drugs 0.000 description 8
• 239000008101 lactose Substances 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 235000019359 magnesium stearate Nutrition 0.000 description 8
• 206010061289 metastatic neoplasm Diseases 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 238000001959 radiotherapy Methods 0.000 description 8
• 150000003839 salts Chemical class 0.000 description 8
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
• 201000009030 Carcinoma Diseases 0.000 description 7
• 108020004414 DNA Proteins 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 229940109239 creatinine Drugs 0.000 description 7
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 7
• 201000001441 melanoma Diseases 0.000 description 7
• 102000039446 nucleic acids Human genes 0.000 description 7
• 108020004707 nucleic acids Proteins 0.000 description 7
• 229960001972 panitumumab Drugs 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 230000008707 rearrangement Effects 0.000 description 7
• 208000013220 shortness of breath Diseases 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 206010041823 squamous cell carcinoma Diseases 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 230000004584 weight gain Effects 0.000 description 7
• 235000019786 weight gain Nutrition 0.000 description 7
• 206010003591 Ataxia Diseases 0.000 description 6
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 6
• 208000001953 Hypotension Diseases 0.000 description 6
• 108060003951 Immunoglobulin Proteins 0.000 description 6
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 6
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 6
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 6
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
• 206010028813 Nausea Diseases 0.000 description 6
• 229930012538 Paclitaxel Natural products 0.000 description 6
• 208000002193 Pain Diseases 0.000 description 6
• 108091000080 Phosphotransferase Proteins 0.000 description 6
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
• 208000006265 Renal cell carcinoma Diseases 0.000 description 6
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
• 206010047513 Vision blurred Diseases 0.000 description 6
• 229940120638 avastin Drugs 0.000 description 6
• 229960000397 bevacizumab Drugs 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 239000012634 fragment Substances 0.000 description 6
• 102000018358 immunoglobulin Human genes 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 229940043355 kinase inhibitor Drugs 0.000 description 6
• 238000002595 magnetic resonance imaging Methods 0.000 description 6
• 230000001394 metastastic effect Effects 0.000 description 6
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
• 239000008108 microcrystalline cellulose Substances 0.000 description 6
• 229940016286 microcrystalline cellulose Drugs 0.000 description 6
• 230000008693 nausea Effects 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 229960001592 paclitaxel Drugs 0.000 description 6
• 230000036407 pain Effects 0.000 description 6
• 102000020233 phosphotransferase Human genes 0.000 description 6
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 5
• 208000000044 Amnesia Diseases 0.000 description 5
• 206010012735 Diarrhoea Diseases 0.000 description 5
• 208000003164 Diplopia Diseases 0.000 description 5
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 5
• 208000032376 Lung infection Diseases 0.000 description 5
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• 206010037660 Pyrexia Diseases 0.000 description 5
• 108091005682 Receptor kinases Proteins 0.000 description 5
• 206010041349 Somnolence Diseases 0.000 description 5
• 206010043276 Teratoma Diseases 0.000 description 5
• 102000005937 Tropomyosin Human genes 0.000 description 5
• 108010030743 Tropomyosin Proteins 0.000 description 5
• 206010047700 Vomiting Diseases 0.000 description 5
• 238000012801 analytical assay Methods 0.000 description 5
• 239000000427 antigen Substances 0.000 description 5
• 108091007433 antigens Proteins 0.000 description 5
• 102000036639 antigens Human genes 0.000 description 5
• 238000003745 diagnosis Methods 0.000 description 5
• 229940120655 eloxatin Drugs 0.000 description 5
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
• 239000000284 extract Substances 0.000 description 5
• 229960002949 fluorouracil Drugs 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 229940014259 gelatin Drugs 0.000 description 5
• 239000007903 gelatin capsule Substances 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 230000036543 hypotension Effects 0.000 description 5
• 238000003780 insertion Methods 0.000 description 5
• 230000037431 insertion Effects 0.000 description 5
• 229960004891 lapatinib Drugs 0.000 description 5
• 201000005202 lung cancer Diseases 0.000 description 5
• 208000020816 lung neoplasm Diseases 0.000 description 5
• 239000002773 nucleotide Substances 0.000 description 5
• 125000003729 nucleotide group Chemical group 0.000 description 5
• 208000035824 paresthesia Diseases 0.000 description 5
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
• 229950008499 plitidepsin Drugs 0.000 description 5
• 108010049948 plitidepsin Proteins 0.000 description 5
• UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 230000002861 ventricular Effects 0.000 description 5
• 230000008673 vomiting Effects 0.000 description 5
• 208000031091 Amnestic disease Diseases 0.000 description 4
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 4
• 201000003076 Angiosarcoma Diseases 0.000 description 4
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 4
• 206010011224 Cough Diseases 0.000 description 4
• 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 4
• 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 206010012218 Delirium Diseases 0.000 description 4
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
• 206010019233 Headaches Diseases 0.000 description 4
• 208000001258 Hemangiosarcoma Diseases 0.000 description 4
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 4
• 208000000112 Myalgia Diseases 0.000 description 4
• 206010033128 Ovarian cancer Diseases 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 4
• 206010034960 Photophobia Diseases 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 description 4
• 206010045170 Tumour lysis syndrome Diseases 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000006986 amnesia Effects 0.000 description 4
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 4
• 229960004977 anhydrous lactose Drugs 0.000 description 4
• 230000000259 anti-tumor effect Effects 0.000 description 4
• 229940041181 antineoplastic drug Drugs 0.000 description 4
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 4
• 238000011260 co-administration Methods 0.000 description 4
• 239000008119 colloidal silica Substances 0.000 description 4
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• 108020001507 fusion proteins Proteins 0.000 description 4
• 102000037865 fusion proteins Human genes 0.000 description 4
• 206010017758 gastric cancer Diseases 0.000 description 4
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
• 208000005017 glioblastoma Diseases 0.000 description 4
• 208000014829 head and neck neoplasm Diseases 0.000 description 4
• 231100000869 headache Toxicity 0.000 description 4
• 201000011066 hemangioma Diseases 0.000 description 4
• 201000005787 hematologic cancer Diseases 0.000 description 4
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
• 238000009396 hybridization Methods 0.000 description 4
• 229960003943 hypromellose Drugs 0.000 description 4
• 238000003364 immunohistochemistry Methods 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 229960004768 irinotecan Drugs 0.000 description 4
• 201000010260 leiomyoma Diseases 0.000 description 4
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 238000002493 microarray Methods 0.000 description 4
• 210000000214 mouth Anatomy 0.000 description 4
• LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 4
• 229960000435 oblimersen Drugs 0.000 description 4
• MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 4
• 229960001756 oxaliplatin Drugs 0.000 description 4
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 4
• WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 4
• 208000022925 sleep disturbance Diseases 0.000 description 4
• 201000011549 stomach cancer Diseases 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 229960001603 tamoxifen Drugs 0.000 description 4
• 229960003433 thalidomide Drugs 0.000 description 4
• 238000010361 transduction Methods 0.000 description 4
• 230000026683 transduction Effects 0.000 description 4
• 238000011269 treatment regimen Methods 0.000 description 4
• 208000010380 tumor lysis syndrome Diseases 0.000 description 4
• 229960000241 vandetanib Drugs 0.000 description 4
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 4
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• XZKUCJJNNDINKX-HGLHLWFZSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4s)-3,4,5-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methoxy]oxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 XZKUCJJNNDINKX-HGLHLWFZSA-N 0.000 description 3
• YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 3
• NECZZOFFLFZNHL-XVGZVFJZSA-N (2s)-2-amino-5-[[(2r)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(r)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 description 3
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
• FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 3
• 206010000087 Abdominal pain upper Diseases 0.000 description 3
• 208000019901 Anxiety disease Diseases 0.000 description 3
• 208000006820 Arthralgia Diseases 0.000 description 3
• 208000012639 Balance disease Diseases 0.000 description 3
• 208000003174 Brain Neoplasms Diseases 0.000 description 3
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 3
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
• 208000002177 Cataract Diseases 0.000 description 3
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 3
• 206010010305 Confusional state Diseases 0.000 description 3
• 206010010774 Constipation Diseases 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 206010014733 Endometrial cancer Diseases 0.000 description 3
• 206010014759 Endometrial neoplasm Diseases 0.000 description 3
• 206010015150 Erythema Diseases 0.000 description 3
• 208000006168 Ewing Sarcoma Diseases 0.000 description 3
• 108700024394 Exon Proteins 0.000 description 3
• 201000008808 Fibrosarcoma Diseases 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
• 108010069236 Goserelin Proteins 0.000 description 3
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 208000004044 Hypesthesia Diseases 0.000 description 3
• 206010021143 Hypoxia Diseases 0.000 description 3
• 108010000817 Leuprolide Proteins 0.000 description 3
• 206010024612 Lipoma Diseases 0.000 description 3
• 229930195725 Mannitol Natural products 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
• 206010027940 Mood altered Diseases 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 3
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 3
• 208000002151 Pleural effusion Diseases 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• 208000010378 Pulmonary Embolism Diseases 0.000 description 3
• 208000015634 Rectal Neoplasms Diseases 0.000 description 3
• 206010057190 Respiratory tract infections Diseases 0.000 description 3
• 208000017442 Retinal disease Diseases 0.000 description 3
• 206010038923 Retinopathy Diseases 0.000 description 3
• 206010040026 Sensory disturbance Diseases 0.000 description 3
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
• 206010041067 Small cell lung cancer Diseases 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 108700011582 TER 286 Proteins 0.000 description 3
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
• 108010050144 Triptorelin Pamoate Proteins 0.000 description 3
• 201000005969 Uveal melanoma Diseases 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 208000034699 Vitreous floaters Diseases 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• 229960002932 anastrozole Drugs 0.000 description 3
• 230000000340 anti-metabolite Effects 0.000 description 3
• 230000001028 anti-proliverative effect Effects 0.000 description 3
• 239000000051 antiandrogen Substances 0.000 description 3
• 229940100197 antimetabolite Drugs 0.000 description 3
• 239000002256 antimetabolite Substances 0.000 description 3
• 230000036506 anxiety Effects 0.000 description 3
• 229960003005 axitinib Drugs 0.000 description 3
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 3
• 229940088954 camptosar Drugs 0.000 description 3
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
• 229960004117 capecitabine Drugs 0.000 description 3
• 229960004562 carboplatin Drugs 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 229960005395 cetuximab Drugs 0.000 description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
• 229960004316 cisplatin Drugs 0.000 description 3
• 229960000928 clofarabine Drugs 0.000 description 3
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 3
• QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 3
• 229940082789 erbitux Drugs 0.000 description 3
• 231100000321 erythema Toxicity 0.000 description 3
• 229960005167 everolimus Drugs 0.000 description 3
• 229960000255 exemestane Drugs 0.000 description 3
• 210000001508 eye Anatomy 0.000 description 3
• 208000020089 femoral neck fracture Diseases 0.000 description 3
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• 229940080856 gleevec Drugs 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 210000003128 head Anatomy 0.000 description 3
• 208000034783 hypoesthesia Diseases 0.000 description 3
• 230000007954 hypoxia Effects 0.000 description 3
• 229960002411 imatinib Drugs 0.000 description 3
• 238000010166 immunofluorescence Methods 0.000 description 3
• 229940072221 immunoglobulins Drugs 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 3
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 206010022437 insomnia Diseases 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 229960003881 letrozole Drugs 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
• 239000007937 lozenge Substances 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 206010027175 memory impairment Diseases 0.000 description 3
• 206010027191 meningioma Diseases 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 229960004857 mitomycin Drugs 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 3
• 230000007510 mood change Effects 0.000 description 3
• 208000024305 myofibroblastoma Diseases 0.000 description 3
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
• 238000007481 next generation sequencing Methods 0.000 description 3
• 229950010203 nimotuzumab Drugs 0.000 description 3
• 201000008968 osteosarcoma Diseases 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 229910052697 platinum Inorganic materials 0.000 description 3
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 208000020016 psychiatric disease Diseases 0.000 description 3
• 206010038038 rectal cancer Diseases 0.000 description 3
• 201000001275 rectum cancer Diseases 0.000 description 3
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
• 208000000587 small cell lung carcinoma Diseases 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 229960003787 sorafenib Drugs 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
• 229960001796 sunitinib Drugs 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 229940034785 sutent Drugs 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 229940120982 tarceva Drugs 0.000 description 3
• 239000011975 tartaric acid Substances 0.000 description 3
• 235000002906 tartaric acid Nutrition 0.000 description 3
• 239000004408 titanium dioxide Substances 0.000 description 3
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 3
• 208000019206 urinary tract infection Diseases 0.000 description 3
• 229960003048 vinblastine Drugs 0.000 description 3
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 3
• 229960002066 vinorelbine Drugs 0.000 description 3
• BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
• DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
• HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 2
• AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 description 2
• VHONNXFZCAICNI-UHFFFAOYSA-N 4-(1h-indol-2-yl)benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=CC=C2N1 VHONNXFZCAICNI-UHFFFAOYSA-N 0.000 description 2
• XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 2
• CTNPALGJUAXMMC-PMFHANACSA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-n-[(2s)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound C([C@@H](O)CNC(=O)C=1C(C)=C(\C=C/2C3=CC(F)=CC=C3NC\2=O)NC=1C)N1CCOCC1 CTNPALGJUAXMMC-PMFHANACSA-N 0.000 description 2
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
• WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
• FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 2
• 208000004998 Abdominal Pain Diseases 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• 206010000599 Acromegaly Diseases 0.000 description 2
• 208000017194 Affective disease Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 206010061424 Anal cancer Diseases 0.000 description 2
• 208000007860 Anus Neoplasms Diseases 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 108090000461 Aurora Kinase A Proteins 0.000 description 2
• 102100032311 Aurora kinase A Human genes 0.000 description 2
• 208000008035 Back Pain Diseases 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• 108010037003 Buserelin Proteins 0.000 description 2
• HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 2
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 206010007275 Carcinoid tumour Diseases 0.000 description 2
• 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 206010010144 Completed suicide Diseases 0.000 description 2
• 208000032170 Congenital Abnormalities Diseases 0.000 description 2
• 206010010356 Congenital anomaly Diseases 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
• 206010012374 Depressed mood Diseases 0.000 description 2
• 206010012559 Developmental delay Diseases 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
• 206010013911 Dysgeusia Diseases 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 2
• QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
• 241001539473 Euphoria Species 0.000 description 2
• 206010015535 Euphoric mood Diseases 0.000 description 2
• 108700012941 GNRH1 Proteins 0.000 description 2
• 206010017577 Gait disturbance Diseases 0.000 description 2
• 206010064571 Gene mutation Diseases 0.000 description 2
• 206010018092 Generalised oedema Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• 208000002927 Hamartoma Diseases 0.000 description 2
• 102000001554 Hemoglobins Human genes 0.000 description 2
• 108010054147 Hemoglobins Proteins 0.000 description 2
• 102000003964 Histone deacetylase Human genes 0.000 description 2
• 108090000353 Histone deacetylase Proteins 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 2
• 241000521257 Hydrops Species 0.000 description 2
• 208000035154 Hyperesthesia Diseases 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 206010061252 Intraocular melanoma Diseases 0.000 description 2
• UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
• 206010022998 Irritability Diseases 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
• 208000018142 Leiomyosarcoma Diseases 0.000 description 2
• 206010067125 Liver injury Diseases 0.000 description 2
• 208000032912 Local swelling Diseases 0.000 description 2
• 206010048961 Localised oedema Diseases 0.000 description 2
• 206010061599 Lower limb fracture Diseases 0.000 description 2
• 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
• 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
• 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
• 208000000172 Medulloblastoma Diseases 0.000 description 2
• XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
• 206010059282 Metastases to central nervous system Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 206010027951 Mood swings Diseases 0.000 description 2
• 208000001089 Multiple system atrophy Diseases 0.000 description 2
• 208000010428 Muscle Weakness Diseases 0.000 description 2
• 206010028372 Muscular weakness Diseases 0.000 description 2
• 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
• 208000009525 Myocarditis Diseases 0.000 description 2
• OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 2
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
• 201000004404 Neurofibroma Diseases 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 206010030124 Oedema peripheral Diseases 0.000 description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
• 206010031127 Orthostatic hypotension Diseases 0.000 description 2
• 206010033733 Papule Diseases 0.000 description 2
• 206010034580 Peripheral motor neuropathy Diseases 0.000 description 2
• 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 208000001431 Psychomotor Agitation Diseases 0.000 description 2
• 238000011529 RT qPCR Methods 0.000 description 2
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 206010038743 Restlessness Diseases 0.000 description 2
• 201000000582 Retinoblastoma Diseases 0.000 description 2
• 206010039163 Right ventricular failure Diseases 0.000 description 2
• 101150035397 Ros1 gene Proteins 0.000 description 2
• 201000010208 Seminoma Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• 206010068771 Soft tissue neoplasm Diseases 0.000 description 2
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
• 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
• 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
• 206010046392 Ureteric cancer Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• 206010046798 Uterine leiomyoma Diseases 0.000 description 2
• 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
• 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
• 208000012886 Vertigo Diseases 0.000 description 2
• 208000021017 Weight Gain Diseases 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• 239000000205 acacia gum Substances 0.000 description 2
• 229960005339 acitretin Drugs 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000002280 anti-androgenic effect Effects 0.000 description 2
• 229940046836 anti-estrogen Drugs 0.000 description 2
• 230000001833 anti-estrogenic effect Effects 0.000 description 2
• 230000003388 anti-hormonal effect Effects 0.000 description 2
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 230000009830 antibody antigen interaction Effects 0.000 description 2
• 201000011165 anus cancer Diseases 0.000 description 2
• 201000007201 aphasia Diseases 0.000 description 2
• 230000004596 appetite loss Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• SHZPNDRIDUBNMH-NIJVSVLQSA-L atorvastatin calcium trihydrate Chemical compound O.O.O.[Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SHZPNDRIDUBNMH-NIJVSVLQSA-L 0.000 description 2
• KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 2
• 230000002146 bilateral effect Effects 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 229960001467 bortezomib Drugs 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
• 229940127093 camptothecin Drugs 0.000 description 2
• 239000003560 cancer drug Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 208000002458 carcinoid tumor Diseases 0.000 description 2
• 229960005243 carmustine Drugs 0.000 description 2
• 229960002412 cediranib Drugs 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 230000008094 contradictory effect Effects 0.000 description 2
• 208000030381 cutaneous melanoma Diseases 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 239000000824 cytostatic agent Substances 0.000 description 2
• 231100000599 cytotoxic agent Toxicity 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 229960003901 dacarbazine Drugs 0.000 description 2
• 229960003603 decitabine Drugs 0.000 description 2
• 206010061428 decreased appetite Diseases 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000018044 dehydration Effects 0.000 description 2
• 238000006297 dehydration reaction Methods 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• 229960000605 dexrazoxane Drugs 0.000 description 2
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
• 208000010643 digestive system disease Diseases 0.000 description 2
• NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 235000019564 dysgeusia Nutrition 0.000 description 2
• BNFRJXLZYUTIII-UHFFFAOYSA-N efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 2
• HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
• 239000000328 estrogen antagonist Substances 0.000 description 2
• NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 229960004945 etoricoxib Drugs 0.000 description 2
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
• 230000003203 everyday effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 208000011318 facial edema Diseases 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 239000012520 frozen sample Substances 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 229960002913 goserelin Drugs 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 231100000753 hepatic injury Toxicity 0.000 description 2
• 210000001624 hip Anatomy 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• XJYNBZQTAZDMHZ-UHFFFAOYSA-N imidacrine Chemical compound O.Cl.Cl.O=C1C2=CC(O)=CC=C2N2C=NC3=CC=C(NCCN(CC)CC)C1=C32 XJYNBZQTAZDMHZ-UHFFFAOYSA-N 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000003119 immunoblot Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 206010022498 insulinoma Diseases 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 238000009533 lab test Methods 0.000 description 2
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
• 229960004338 leuprorelin Drugs 0.000 description 2
• 229940002661 lipitor Drugs 0.000 description 2
• 206010024627 liposarcoma Diseases 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 208000019017 loss of appetite Diseases 0.000 description 2
• 235000021266 loss of appetite Nutrition 0.000 description 2
• 229960004844 lovastatin Drugs 0.000 description 2
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 229940124302 mTOR inhibitor Drugs 0.000 description 2
• 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 2
• 208000026037 malignant tumor of neck Diseases 0.000 description 2
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
• 229950001869 mapatumumab Drugs 0.000 description 2
• 210000001370 mediastinum Anatomy 0.000 description 2
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
• 230000037230 mobility Effects 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 2
• 201000002239 motor neuritis Diseases 0.000 description 2
• 201000005545 motor peripheral neuropathy Diseases 0.000 description 2
• 229950007221 nedaplatin Drugs 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 229940080607 nexavar Drugs 0.000 description 2
• 201000002575 ocular melanoma Diseases 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 108700027936 paclitaxel poliglumex Proteins 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 208000021255 pancreatic insulinoma Diseases 0.000 description 2
• 229960004662 parecoxib Drugs 0.000 description 2
• TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 2
• 229960003349 pemetrexed disodium Drugs 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
• 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
• 229960003452 romidepsin Drugs 0.000 description 2
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
• 108010091666 romidepsin Proteins 0.000 description 2
• WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
• 229960005399 satraplatin Drugs 0.000 description 2
• 190014017285 satraplatin Chemical compound 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 208000011571 secondary malignant neoplasm Diseases 0.000 description 2
• 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
• BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
• 229950000055 seliciclib Drugs 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
• 201000003708 skin melanoma Diseases 0.000 description 2
• 239000012748 slip agent Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 229960000894 sulindac Drugs 0.000 description 2
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229960004964 temozolomide Drugs 0.000 description 2
• 229950006156 teprenone Drugs 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
• 229960000303 topotecan Drugs 0.000 description 2
• PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 229960004824 triptorelin Drugs 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
• 208000019553 vascular disease Diseases 0.000 description 2
• 229950000578 vatalanib Drugs 0.000 description 2
• 231100000889 vertigo Toxicity 0.000 description 2
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 229940053867 xeloda Drugs 0.000 description 2
• 229940004212 yondelis Drugs 0.000 description 2
• XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
• LKEPMZXBLXKDRN-BYPYZUCNSA-N (2S)-5-amino-2-(fluoroamino)pentanoic acid Chemical compound NCCC[C@H](NF)C(O)=O LKEPMZXBLXKDRN-BYPYZUCNSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• RIWLPSIAFBLILR-WVNGMBSFSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2r,3s)-2-[[(2s)-2-[[2-[[2-[acetyl(methyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethy Chemical compound CC(=O)N(C)CC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC RIWLPSIAFBLILR-WVNGMBSFSA-N 0.000 description 1
• AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 description 1
• GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 description 1
• NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• ZUXIYCHITJQXIU-UHFFFAOYSA-N 10-[3-[4-[2-(1,3-dioxan-2-yl)ethyl]piperazin-1-yl]propyl]phenothiazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CCCN(CC1)CCN1CCC1OCCCO1 ZUXIYCHITJQXIU-UHFFFAOYSA-N 0.000 description 1
• ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
• KUFRQPKVAWMTJO-QSTRRNJOSA-N 17-dmag Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-QSTRRNJOSA-N 0.000 description 1
• ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
• FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
• PJKVJJYMWOCLIJ-UHFFFAOYSA-N 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-1h-quinazolin-4-one;hydron;dichloride Chemical compound Cl.Cl.CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 PJKVJJYMWOCLIJ-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• ZUDXUNPSRMREOJ-UHFFFAOYSA-N 3-(4-methoxyphenyl)-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2h-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C(COC1=CC(O)=CC=C11)=C1CC(C=C1)=CC=C1OCCN1CCCCC1 ZUDXUNPSRMREOJ-UHFFFAOYSA-N 0.000 description 1
• KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
• QFCXANHHBCGMAS-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C=3OC=CC=3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 QFCXANHHBCGMAS-UHFFFAOYSA-N 0.000 description 1
• HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
• JFIWEPHGRUDAJN-DYUFWOLASA-N 4-amino-1-[(2r,3r,4s,5r)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@](O)(C#C)[C@@H](CO)O1 JFIWEPHGRUDAJN-DYUFWOLASA-N 0.000 description 1
• AKJHMTWEGVYYSE-FXILSDISSA-N 4-hydroxyphenyl retinamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
• WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
• DQOGWKZQQBYYMW-LQGIGNHCSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 DQOGWKZQQBYYMW-LQGIGNHCSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• SJUWEPZBTXEUMU-LDXVYITESA-N 7-bromo-6-chloro-3-[3-[(2s,3r)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;hydrobromide Chemical compound Br.O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 SJUWEPZBTXEUMU-LDXVYITESA-N 0.000 description 1
• PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
• 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
• PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
• 101150023956 ALK gene Proteins 0.000 description 1
• 208000010962 ALK-positive anaplastic large cell lymphoma Diseases 0.000 description 1
• 206010000097 Abdominal tenderness Diseases 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 239000004382 Amylase Substances 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 102100022987 Angiogenin Human genes 0.000 description 1
• 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• MAVDNGWEBZTACC-HNNXBMFYSA-N Apratastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C1=CC=C(OCC#CCO)C=C1 MAVDNGWEBZTACC-HNNXBMFYSA-N 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 102100032306 Aurora kinase B Human genes 0.000 description 1
• 108090000749 Aurora kinase B Proteins 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• OLCWFLWEHWLBTO-HSZRJFAPSA-N BMS-214662 Chemical compound C=1C=CSC=1S(=O)(=O)N([C@@H](C1)CC=2C=CC=CC=2)CC2=CC(C#N)=CC=C2N1CC1=CN=CN1 OLCWFLWEHWLBTO-HSZRJFAPSA-N 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 244000056139 Brassica cretica Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• 206010006417 Bronchial carcinoma Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 229940124204 C-kit inhibitor Drugs 0.000 description 1
• 101100326430 Caenorhabditis elegans bub-1 gene Proteins 0.000 description 1
• 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 1
• 101100498823 Caenorhabditis elegans ddr-2 gene Proteins 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
• AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
• 206010007748 Cataract cortical Diseases 0.000 description 1
• 206010008263 Cervical dysplasia Diseases 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 201000005262 Chondroma Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010048832 Colon adenoma Diseases 0.000 description 1
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
• 206010065859 Congenital fibrosarcoma Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 206010011013 Corneal erosion Diseases 0.000 description 1
• 102000016736 Cyclin Human genes 0.000 description 1
• 108050006400 Cyclin Proteins 0.000 description 1
• 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
• 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 1
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 229960005500 DHA-paclitaxel Drugs 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• 108010002156 Depsipeptides Proteins 0.000 description 1
• 101000651218 Dictyostelium discoideum Dual specificity protein kinase splA Proteins 0.000 description 1
• 241000255925 Diptera Species 0.000 description 1
• 206010013786 Dry skin Diseases 0.000 description 1
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 101150039808 Egfr gene Proteins 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 208000007207 Epithelioid hemangioendothelioma Diseases 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 201000001342 Fallopian tube cancer Diseases 0.000 description 1
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016454 Femur fracture Diseases 0.000 description 1
• 208000007659 Fibroadenoma Diseases 0.000 description 1
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
• 206010016667 Fibula fracture Diseases 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• 206010016970 Foot fracture Diseases 0.000 description 1
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 206010073420 Genital paraesthesia Diseases 0.000 description 1
• 208000021309 Germ cell tumor Diseases 0.000 description 1
• 208000007569 Giant Cell Tumors Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102000051325 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 206010018404 Glucagonoma Diseases 0.000 description 1
• NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 206010019075 Hallucination, visual Diseases 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 206010019629 Hepatic adenoma Diseases 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
• 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
• 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
• 208000007981 Humeral Fractures Diseases 0.000 description 1
• 206010020462 Humerus fracture Diseases 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000002682 Hyperkalemia Diseases 0.000 description 1
• 208000029422 Hypernatremia Diseases 0.000 description 1
• 206010058490 Hyperoxia Diseases 0.000 description 1
• 208000003623 Hypoalbuminemia Diseases 0.000 description 1
• 208000013038 Hypocalcemia Diseases 0.000 description 1
• 208000029663 Hypophosphatemia Diseases 0.000 description 1
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000003781 Inhibitor of growth protein 1 Human genes 0.000 description 1
• 108090000191 Inhibitor of growth protein 1 Proteins 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
• 229940123830 K-Ras inhibitor Drugs 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• 206010023347 Keratoacanthoma Diseases 0.000 description 1
• 102000010638 Kinesin Human genes 0.000 description 1
• 108010063296 Kinesin Proteins 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
• 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 206010023804 Large intestine perforation Diseases 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
• 206010025327 Lymphopenia Diseases 0.000 description 1
• 229940124647 MEK inhibitor Drugs 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 108020005196 Mitochondrial DNA Proteins 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
• 208000023178 Musculoskeletal disease Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• NFIXBCVWIPOYCD-UHFFFAOYSA-N N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 description 1
• URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 1
• LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 108010072915 NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt Proteins 0.000 description 1
• WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010028836 Neck pain Diseases 0.000 description 1
• 208000034827 Neointima Diseases 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 241000232901 Nephroma Species 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 241000159206 Nitraria Species 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 208000000035 Osteochondroma Diseases 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 102000038030 PI3Ks Human genes 0.000 description 1
• 206010033425 Pain in extremity Diseases 0.000 description 1
• SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
• 241000282373 Panthera pardus Species 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 244000303512 Peucedanum ostruthium Species 0.000 description 1
• 241001505935 Phalaenopsis Species 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 201000005746 Pituitary adenoma Diseases 0.000 description 1
• 206010061538 Pituitary tumour benign Diseases 0.000 description 1
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 241000282335 Procyon Species 0.000 description 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 102100024923 Protein kinase C beta type Human genes 0.000 description 1
• 101710094033 Protein kinase C beta type Proteins 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108020001991 Protoporphyrinogen Oxidase Proteins 0.000 description 1
• 102000005135 Protoporphyrinogen oxidase Human genes 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 206010037423 Pulmonary oedema Diseases 0.000 description 1
• 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
• 101150101372 RAF1 gene Proteins 0.000 description 1
• 206010037868 Rash maculo-papular Diseases 0.000 description 1
• 206010037884 Rash pruritic Diseases 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 208000037656 Respiratory Sounds Diseases 0.000 description 1
• QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
• 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
• 208000005678 Rhabdomyoma Diseases 0.000 description 1
• 208000027790 Rib fracture Diseases 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
• 229940119564 Selective estrogen receptor downregulator Drugs 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 1
• 101710148155 Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 1
• 208000032023 Signs and Symptoms Diseases 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 208000019498 Skin and subcutaneous tissue disease Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 208000005250 Spontaneous Fractures Diseases 0.000 description 1
• UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
• UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 208000013201 Stress fracture Diseases 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 208000005400 Synovial Cyst Diseases 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
• HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 238000005411 Van der Waals force Methods 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• 208000035307 Vitreous adhesions Diseases 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 206010047924 Wheezing Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 206010048049 Wrist fracture Diseases 0.000 description 1
• 206010048214 Xanthoma Diseases 0.000 description 1
• 206010048215 Xanthomatosis Diseases 0.000 description 1
• YVPOVOVZCOOSBQ-AXHZAXLDSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 YVPOVOVZCOOSBQ-AXHZAXLDSA-N 0.000 description 1
• RTJVUHUGTUDWRK-CSLCKUBZSA-N [(2r,4ar,6r,7r,8s,8ar)-6-[[(5s,5ar,8ar,9r)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]d Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](OC(=O)COC=4C(=C(F)C(F)=C(F)C=4F)F)[C@@H]4O[C@H](C)OC[C@H]4O3)OC(=O)COC=3C(=C(F)C(F)=C(F)C=3F)F)[C@@H]3[C@@H]2C(OC3)=O)=C1 RTJVUHUGTUDWRK-CSLCKUBZSA-N 0.000 description 1
• LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
• XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
• GSOXMQLWUDQTNT-WAYWQWQTSA-N [3-methoxy-2-phosphonooxy-6-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 GSOXMQLWUDQTNT-WAYWQWQTSA-N 0.000 description 1
• 108010023617 abarelix Proteins 0.000 description 1
• AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
• 229960002184 abarelix Drugs 0.000 description 1
• 206010000059 abdominal discomfort Diseases 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
• 238000011226 adjuvant chemotherapy Methods 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 229940034653 advicor Drugs 0.000 description 1
• 108010081667 aflibercept Proteins 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 229940060515 aleve Drugs 0.000 description 1
• 229940110282 alimta Drugs 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 208000012759 altered mental status Diseases 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 229950010817 alvocidib Drugs 0.000 description 1
• BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 229960002550 amrubicin Drugs 0.000 description 1
• VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 108010072788 angiogenin Proteins 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000013059 antihormonal agent Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 229940078010 arimidex Drugs 0.000 description 1
• 229940087620 aromasin Drugs 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 210000000544 articulatio talocruralis Anatomy 0.000 description 1
• 229950000847 ascrinvacumab Drugs 0.000 description 1
• PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
• 229950004810 atamestane Drugs 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 208000019804 backache Diseases 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 229950001429 batabulin Drugs 0.000 description 1
• NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
• 229950011276 belotecan Drugs 0.000 description 1
• LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
• 229960002707 bendamustine Drugs 0.000 description 1
• YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
• NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 1
• 229960002938 bexarotene Drugs 0.000 description 1
• 229940110331 bextra Drugs 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• UBJAHGAUPNGZFF-XOVTVWCYSA-N bms-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 201000006491 bone marrow cancer Diseases 0.000 description 1
• 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
• 201000003149 breast fibroadenoma Diseases 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• 229960002719 buserelin Drugs 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• GWFBXGWIRCSOAO-UHFFFAOYSA-N butanedioic acid;2-(1-propylpiperidin-4-yl)-1h-benzimidazole-4-carboxamide Chemical compound OC(=O)CCC(O)=O.C1CN(CCC)CCC1C1=NC2=C(C(N)=O)C=CC=C2N1 GWFBXGWIRCSOAO-UHFFFAOYSA-N 0.000 description 1
• GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 description 1
• 229940022418 caduet Drugs 0.000 description 1
• AKUPTUNGFOADRT-ZEDZUCNESA-L calcium;(2s)-2-[[4-(3-amino-1-oxo-4,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl)benzoyl]amino]pentanedioate Chemical compound [Ca+2].C1C2CNC=3NC(N)=NC(=O)C=3N2CN1C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 AKUPTUNGFOADRT-ZEDZUCNESA-L 0.000 description 1
• 229940022399 cancer vaccine Drugs 0.000 description 1
• 238000009566 cancer vaccine Methods 0.000 description 1
• 229950002826 canertinib Drugs 0.000 description 1
• OJLHWPALWODJPQ-QNWVGRARSA-N canfosfamide Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 OJLHWPALWODJPQ-QNWVGRARSA-N 0.000 description 1
• 229950000772 canfosfamide Drugs 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 239000007963 capsule composition Substances 0.000 description 1
• 229960003261 carmofur Drugs 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 229960000419 catumaxomab Drugs 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 208000025997 central nervous system neoplasm Diseases 0.000 description 1
• 229960005110 cerivastatin Drugs 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 101150113535 chek1 gene Proteins 0.000 description 1
• IQCIQDNWBGEGRL-UHFFFAOYSA-N chembl1614651 Chemical compound O=C1C2=C(O)C=CC(O)=C2N2N=C(CNCCO)C3=CC=C(NCCCN)C1=C32 IQCIQDNWBGEGRL-UHFFFAOYSA-N 0.000 description 1
• ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 238000009104 chemotherapy regimen Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 230000008711 chromosomal rearrangement Effects 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 229950009003 cilengitide Drugs 0.000 description 1
• AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
• 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 229940103380 clolar Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 208000029511 cortical cataract Diseases 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 229940066901 crestor Drugs 0.000 description 1
• 229960005061 crizotinib Drugs 0.000 description 1
• 230000037029 cross reaction Effects 0.000 description 1
• GOHCTCOGYKAJLZ-UHFFFAOYSA-N ctep Chemical compound CC=1N(C=2C=CC(OC(F)(F)F)=CC=2)C(C)=NC=1C#CC1=CC=NC(Cl)=C1 GOHCTCOGYKAJLZ-UHFFFAOYSA-N 0.000 description 1
• 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
• PZAQDVNYNJBUTM-UHFFFAOYSA-L cyclohexane-1,2-diamine;7,7-dimethyloctanoate;platinum(2+) Chemical compound [Pt+2].NC1CCCCC1N.CC(C)(C)CCCCCC([O-])=O.CC(C)(C)CCCCCC([O-])=O PZAQDVNYNJBUTM-UHFFFAOYSA-L 0.000 description 1
• 229960003843 cyproterone Drugs 0.000 description 1
• DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 229940059359 dacogen Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229940070230 daypro Drugs 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• LRCZQSDQZJBHAF-PUBGEWHCSA-N dha-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• ZKKLPDLKUGTPME-UHFFFAOYSA-N diazanium;bis(sulfanylidene)molybdenum;sulfanide Chemical compound [NH4+].[NH4+].[SH-].[SH-].S=[Mo]=S ZKKLPDLKUGTPME-UHFFFAOYSA-N 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• LFQCJSBXBZRMTN-OAQYLSRUSA-N diflomotecan Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC(F)=C(F)C=C3N=C21 LFQCJSBXBZRMTN-OAQYLSRUSA-N 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 235000021186 dishes Nutrition 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 229940072701 dolobid Drugs 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 230000037336 dry skin Effects 0.000 description 1
• JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
• 229960004199 dutasteride Drugs 0.000 description 1
• 201000006549 dyspepsia Diseases 0.000 description 1
• 210000000959 ear middle Anatomy 0.000 description 1
• 229960000925 efaproxiral Drugs 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 201000011523 endocrine gland cancer Diseases 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 208000023437 ependymal tumor Diseases 0.000 description 1
• 230000001973 epigenetic effect Effects 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 201000005619 esophageal carcinoma Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• ISJSHQTWOHGCMM-NDEPHWFRSA-N ethyl 4-[(2s)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NS(=O)(=O)C=1C(=CC(=CC=1C(C)C)C(C)C)C(C)C)CC1=CC=CC(C(N)=N)=C1 ISJSHQTWOHGCMM-NDEPHWFRSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 229950000484 exisulind Drugs 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 229950011548 fadrozole Drugs 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 229940065410 feldene Drugs 0.000 description 1
• 229940087476 femara Drugs 0.000 description 1
• 206010016629 fibroma Diseases 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
• 229960004039 finasteride Drugs 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 229930003935 flavonoid Natural products 0.000 description 1
• 150000002215 flavonoids Chemical class 0.000 description 1
• 235000017173 flavonoids Nutrition 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• 229960004421 formestane Drugs 0.000 description 1
• OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 229960002258 fulvestrant Drugs 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 210000005095 gastrointestinal system Anatomy 0.000 description 1
• 208000018685 gastrointestinal system disease Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
• 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229920000591 gum Polymers 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 230000010224 hepatic metabolism Effects 0.000 description 1
• 208000024557 hepatobiliary disease Diseases 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 201000002735 hepatocellular adenoma Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000004754 hybrid cell Anatomy 0.000 description 1
• 229940088013 hycamtin Drugs 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 230000000222 hyperoxic effect Effects 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 230000000705 hypocalcaemia Effects 0.000 description 1
• 210000003026 hypopharynx Anatomy 0.000 description 1
• 229960005236 ibandronic acid Drugs 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229950003909 iguratimod Drugs 0.000 description 1
• 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 201000004933 in situ carcinoma Diseases 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
• 229960004078 indacaterol Drugs 0.000 description 1
• 229950009881 indisulam Drugs 0.000 description 1
• 229940089536 indocin Drugs 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000012739 integrated shape imaging system Methods 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 239000012444 intercalating antibiotic Substances 0.000 description 1
• 108010072729 interleukin-4-Pseudomonas exotoxin Proteins 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• 239000004407 iron oxides and hydroxides Substances 0.000 description 1
• 201000002529 islet cell tumor Diseases 0.000 description 1
• 239000003394 isomerase inhibitor Substances 0.000 description 1
• 230000007803 itching Effects 0.000 description 1
• 229960002014 ixabepilone Drugs 0.000 description 1
• FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
• UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 229960004752 ketorolac Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 229950003970 larotrectinib Drugs 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 229960004942 lenalidomide Drugs 0.000 description 1
• 229940095570 lescol Drugs 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 208000013469 light sensitivity Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 210000000088 lip Anatomy 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 238000007449 liver function test Methods 0.000 description 1
• 229950008991 lobaplatin Drugs 0.000 description 1
• 229940063718 lodine Drugs 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 229940076783 lucentis Drugs 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• 208000022766 lymph node neoplasm Diseases 0.000 description 1
• 201000007275 lymphatic system cancer Diseases 0.000 description 1
• 231100001023 lymphopenia Toxicity 0.000 description 1
• 229940092110 macugen Drugs 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 201000004593 malignant giant cell tumor Diseases 0.000 description 1
• 201000000289 malignant teratoma Diseases 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229950008001 matuzumab Drugs 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• 229960004616 medroxyprogesterone Drugs 0.000 description 1
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 229940090004 megace Drugs 0.000 description 1
• 229960001786 megestrol Drugs 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000006371 metabolic abnormality Effects 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 208000037843 metastatic solid tumor Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 229940099246 mevacor Drugs 0.000 description 1
• BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
• 229950010895 midostaurin Drugs 0.000 description 1
• 229960003248 mifepristone Drugs 0.000 description 1
• PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• AARXZCZYLAFQQU-UHFFFAOYSA-N motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
• 229940072709 motrin Drugs 0.000 description 1
• ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
• 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
• 238000007837 multiplex assay Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 208000009091 myxoma Diseases 0.000 description 1
• LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 229940090008 naprosyn Drugs 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 210000001989 nasopharynx Anatomy 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• 229960000801 nelarabine Drugs 0.000 description 1
• IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
• 229950010159 nemorubicin Drugs 0.000 description 1
• CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
• QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
• 230000008692 neointimal formation Effects 0.000 description 1
• 208000025351 nephroma Diseases 0.000 description 1
• 208000009928 nephrosis Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 230000000508 neurotrophic effect Effects 0.000 description 1
• 229940063708 neutrexin Drugs 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229940099637 nilandron Drugs 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
• 231100001221 nontumorigenic Toxicity 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 208000030212 nutrition disease Diseases 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• YVPOTNAPPSUMJX-UHFFFAOYSA-N octadecanoic acid;phosphoric acid Chemical compound OP(O)(O)=O.CCCCCCCCCCCCCCCCCC(O)=O YVPOTNAPPSUMJX-UHFFFAOYSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 229950003600 ombrabulin Drugs 0.000 description 1
• IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 1
• 229940099216 oncaspar Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 210000003300 oropharynx Anatomy 0.000 description 1
• 208000003388 osteoid osteoma Diseases 0.000 description 1
• 208000008798 osteoma Diseases 0.000 description 1
• 229940127075 other antimetabolite Drugs 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 229960004390 palbociclib Drugs 0.000 description 1
• 230000009996 pancreatic endocrine effect Effects 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
• 210000003695 paranasal sinus Anatomy 0.000 description 1
• 230000000849 parathyroid Effects 0.000 description 1
• 210000003681 parotid gland Anatomy 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
• LXCWYTUKZXZSAJ-AUHBJGJSSA-N pck 3145 Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=C(O)C=C1 LXCWYTUKZXZSAJ-AUHBJGJSSA-N 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 229960003407 pegaptanib Drugs 0.000 description 1
• 108010001564 pegaspargase Proteins 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
• 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 229960002087 pertuzumab Drugs 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 229960001221 pirarubicin Drugs 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• 208000021310 pituitary gland adenoma Diseases 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 230000001144 postural effect Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940116317 potato starch Drugs 0.000 description 1
• 229940089484 pravachol Drugs 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
• 239000003197 protein kinase B inhibitor Substances 0.000 description 1
• 208000005333 pulmonary edema Diseases 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 201000001722 pulmonary large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 239000000649 purine antagonist Substances 0.000 description 1
• 210000003065 pyriform sinus Anatomy 0.000 description 1
• 239000003790 pyrimidine antagonist Substances 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 102000009929 raf Kinases Human genes 0.000 description 1
• 108010077182 raf Kinases Proteins 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004432 raltitrexed Drugs 0.000 description 1
• 229960003876 ranibizumab Drugs 0.000 description 1
• 108010061338 ranpirnase Proteins 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 229940087462 relafen Drugs 0.000 description 1
• 210000004994 reproductive system Anatomy 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
• 235000021283 resveratrol Nutrition 0.000 description 1
• 229940016667 resveratrol Drugs 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 210000000574 retroperitoneal space Anatomy 0.000 description 1
• 229940120975 revlimid Drugs 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
• 229960001225 rifampicin Drugs 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• 229960000672 rosuvastatin Drugs 0.000 description 1
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
• LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
• 229960000953 salsalate Drugs 0.000 description 1
• 229950009919 saracatinib Drugs 0.000 description 1
• OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
• 239000010018 saw palmetto extract Substances 0.000 description 1
• 229940063845 saw palmetto extract Drugs 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 238000006748 scratching Methods 0.000 description 1
• 230000002393 scratching effect Effects 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 229940125944 selective estrogen receptor degrader Drugs 0.000 description 1
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 201000001839 skull cancer Diseases 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 230000027849 smooth muscle hyperplasia Effects 0.000 description 1
• DZMVCVHATYROOS-ZBFGKEHZSA-N soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 1
• 108010047846 soblidotin Proteins 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 206010041569 spinal fracture Diseases 0.000 description 1
• 229950001248 squalamine Drugs 0.000 description 1
• 102000009076 src-Family Kinases Human genes 0.000 description 1
• 108010087686 src-Family Kinases Proteins 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 210000004304 subcutaneous tissue Anatomy 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• MVGSNCBCUWPVDA-MFOYZWKCSA-N sulindac sulfone Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 229950003999 tafluposide Drugs 0.000 description 1
• 229940099419 targretin Drugs 0.000 description 1
• 229960001674 tegafur Drugs 0.000 description 1
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
• 229940061353 temodar Drugs 0.000 description 1
• 229960000235 temsirolimus Drugs 0.000 description 1
• 229950003046 tesevatinib Drugs 0.000 description 1
• 229950007967 tesmilifene Drugs 0.000 description 1
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
• 229940034915 thalomid Drugs 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 229950002376 tirapazamine Drugs 0.000 description 1
• QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 229960003989 tocilizumab Drugs 0.000 description 1
• 229960001017 tolmetin Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229940019127 toradol Drugs 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 229940100411 torisel Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 229940032510 trelstar Drugs 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
• 229960001099 trimetrexate Drugs 0.000 description 1
• 208000022271 tubular adenoma Diseases 0.000 description 1
• 239000003744 tubulin modulator Substances 0.000 description 1
• 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 229940094060 tykerb Drugs 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 108010002164 tyrosine receptor Proteins 0.000 description 1
• HDYANYHVCAPMJV-USQUEEHTSA-N udp-glucuronic acid Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)[C@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HDYANYHVCAPMJV-USQUEEHTSA-N 0.000 description 1
• AHXICHPPXIGCBN-GPWPDEGDSA-N uqc681jjiv Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)OC)C(=O)C1=CC=CC=C1 AHXICHPPXIGCBN-GPWPDEGDSA-N 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 208000014001 urinary system disease Diseases 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 229950008737 vadimezan Drugs 0.000 description 1
• XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 229960002004 valdecoxib Drugs 0.000 description 1
• 229960000653 valrubicin Drugs 0.000 description 1
• ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 201000011531 vascular cancer Diseases 0.000 description 1
• 206010055031 vascular neoplasm Diseases 0.000 description 1
• 239000004066 vascular targeting agent Substances 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 229940099039 velcade Drugs 0.000 description 1
• 229940065658 vidaza Drugs 0.000 description 1
• 208000009540 villous adenoma Diseases 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960000922 vinflunine Drugs 0.000 description 1
• NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 229940087652 vioxx Drugs 0.000 description 1
• 208000000318 vitreous detachment Diseases 0.000 description 1
• 229940063674 voltaren Drugs 0.000 description 1
• 229960000237 vorinostat Drugs 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 229940121396 wnt pathway inhibitor Drugs 0.000 description 1
• ZPUHVPYXSITYDI-HEUWMMRCSA-N xyotax Chemical compound OC(=O)[C@@H](N)CCC(O)=O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 ZPUHVPYXSITYDI-HEUWMMRCSA-N 0.000 description 1
• UGBMEXLBFDAOGL-INIZCTEOSA-N zd6126 Chemical compound C1C[C@H](NC(C)=O)C2=CC(OP(O)(O)=O)=CC=C2C2=C1C=C(OC)C(OC)=C2OC UGBMEXLBFDAOGL-INIZCTEOSA-N 0.000 description 1
• 229950009268 zinostatin Drugs 0.000 description 1
• 229940072168 zocor Drugs 0.000 description 1
• 229940033942 zoladex Drugs 0.000 description 1
• 229960004276 zoledronic acid Drugs 0.000 description 1
• 229940061261 zolinza Drugs 0.000 description 1
• 229940002005 zometa Drugs 0.000 description 1